Active	Status	Sponsor type	Region	Phase	Filter
12 Active 2 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mims, Alice
NCT04801797: Venetoclax + Azacitidine vs. Induction Chemotherapy in AML	Recruiting	2	172	US	Cytarabine, Ara-C, Arabinosylcytosine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Vyxeos, Venetoclax, Venclexta, Azacitidine, Vidaza	Massachusetts General Hospital, AbbVie	Acute Myeloid Leukemia	01/25	01/26
NCT04284228: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT	Active, not recruiting	1/2	22	US	Infusion of NEXI-001 T Cells	NexImmune Inc.	Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)	10/24	03/25
TWT-202, NCT04730258: A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML	Recruiting	1/2	72	Canada, US, RoW	CFI-400945, CFI-400945 fumarate, 945, 400945, Azacitidine	Treadwell Therapeutics, Inc	Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML	01/26	01/26
NCT04764474: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH	Recruiting	1	75	Europe, US	HMPL-306	Hutchmed	Isocitrate Dehydrogenase Gene Mutation	09/24	06/25
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML	Recruiting	1	50	US	Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®	Oryzon Genomics S.A.	Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory	11/25	11/25
SGR-2921-101, NCT05961839: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Recruiting	1	50	US	SGR-2921	Schrödinger, Inc.	Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes	12/25	12/25